Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [Thoracic Oncology]

Conclusion
Consistent with its activity in ASCEND-1, ceritinib treatment provided clinically meaningful and durable responses with manageable tolerability in chemotherapy- and crizotinib-pretreated patients, including those with brain metastases.

Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Crino, Ahn, De Marinis, Groen, Wakelee, Hida, Mok, Spigel, Felip, Nishio, Scagliotti, Branle, Emeremni, Quadrigli, Zhang, Shaw Tags: Chemotherapy Thoracic Oncology Source Type: research